By Application
Hot products 
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-ALDOA Recombinant Antibody (A2) (CBMAB-A2316-YC)
-
Rat Anti-(1-5)-α-L-Arabinan Recombinant Antibody (V2-501861) (CBMAB-XB0003-YC)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Rabbit Anti-CCN1 Recombinant Antibody (CBWJC-3580) (CBMAB-C4816WJ)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Mouse Anti-ARID1B Recombinant Antibody (KMN1) (CBMAB-A3546-YC)
-
Mouse Anti-CA9 Recombinant Antibody (CBXC-2079) (CBMAB-C0131-CQ)
-
Mouse Anti-ENO2 Recombinant Antibody (H14) (CBMAB-E1341-FY)
-
Mouse Anti-CD83 Recombinant Antibody (HB15) (CBMAB-C1765-CQ)
-
Rat Anti-ADGRE4 Recombinant Antibody (V2-160163) (CBMAB-F0011-CQ)
-
Mouse Anti-FOSB Recombinant Antibody (CBXF-3593) (CBMAB-F2522-CQ)
-
Mouse Anti-CD24 Recombinant Antibody (ALB9) (CBMAB-0176CQ)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-BAX Recombinant Antibody (CBYY-0216) (CBMAB-0217-YY)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Mouse Anti-AGO2 Recombinant Antibody (V2-634169) (CBMAB-AP203LY)
-
Mouse Anti-ENO2 Recombinant Antibody (85F11) (CBMAB-0276CQ)
Breast Cancer
Fig.1 Breast cancer
Breast cancer is mainly considered to develop in cells from the lining of milk ducts and the lobules that produce the milk, which is known as ductal carcinomas and lobular carcinomas. Risk factors giving rise to breast cancer include being female, obesity, lacking of physical exercise and so on. Signs of breast cancer may include a red scaly patch of skin, a lump in the breast, a change in breast shape, dimpling of the skin or fluid coming from the nipple. About 5–10% of cases can be attributed to genes inherited from a person's parents, including BRCA1 and BRCA2 among others. The diagnosis of breast cancer can be confirmed by taking a biopsy of the concerning lump. In addition, when the diagnosis is made, further tests need to be done to determine if the cancer has spread beyond the breast and which treatments it may respond to. Clinically, the most useful metabolic markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. HER-2 and SCD1 predict response to therapeutic regimens, and urokinase plasminogen activators (PA1-1 and SCD1) are used for assessing prognosis.
Loading...
Compare
